MG 患者长程管理目标是什么?长程管理的意义是什么?
查看病例


参考文献
[1] 常婷. 中国重症肌无力诊断和治疗指南(2020 版)[J]. 中国神经免疫学和神经病学杂志, 2021,28(01):1-12.
[2] Nelke C, Stascheit F, Eckert C, et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients[J]. J Neuroinflammation, 2022,19(1):89.
[3] Wiendl H, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240.
[4] 中国罕见病联盟神经罕见病专业委员会,中国罕见病联盟重症肌无力协作组,中华医学会神经病学分会神经肌肉病学组. 中国难治性全身型重症肌无力诊断和治疗专家共识(2024版)[J]. 中华神经科杂志,2024,57(08):840-847.
[5] Muppidi S, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14-24.
[6] Takahashi M,et al. Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Effectiveness, concomitant oral corticosteroid use and safety data from post-marketing surveillance. EAN-2023 eposter:EPO-396.
[7] Howard JF Jr, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023 May;22(5):395-406.
最后编辑于 03-20 · 浏览 1274